References
- Capoluongo, E.D., Amato, F., Castaldo, G. (2020). The friendly use of
chloroquine in the COVID-19 disease: a warning for the G6PD-deficient
males and for the unaware carriers of pathogenic alterations of the
G6PD gene. Clin Chem Lab Med . 2020 Clin Chem Lab Med, 2020 Apr
24:/j/cclm.ahead-of-print/cclm-2020-0442/cclm-2020-0442.xml
- Tang, N., Bai, H., Chen, X., Gong, J., Li, D., Sun, Z. (2020).
Anticoagulant treatment is associated with decreased mortality in
severe coronavirus disease 2019 patients with coagulopathy. J
Thromb Haemost , 2020;18(5):1094-1099.
- Thachil, J., Tang, N., Gando, S., Falanga, A., Cattaneo, M., Levi, M.,
Clark, C., Iba, T. (2020). ISTH interim guidance on recognition and
management of coagulopathy in COVID-19. J Thromb Hemost ,
18(5):1023-1026
- Chan, K.W., Wong, V.T., Tang, S.C.W. (2020). COVID-19: An Update on
the Epidemiological, Clinical, Preventive and Therapeutic Evidence and
Guidelines of Integrative Chinese-Western Medicine for the Management
of 2019 Novel Coronavirus Disease. Am J Chin Med ,
48(3):737-762.
- Berger, N.A., Besson, V.C., Boulares, A.H., et al .(2018).
Opportunities for the repurposing of PARP inhibitors for the therapy
of non-oncological diseases. Br J Pharmacol;175:192-222.
- Capoluongo, E. (2016). BRCA to the future: towards best testing
practice in the era of personalised healthcare. Eur J Hum
Genet , 1:S1-2;
- Mathews, M.T., Berk, B.C.(2008). PARP-1 inhibition prevents oxidative
and nitrosative stress-induced endothelial cell death via
transactivation of the VEGF receptor 2. Arterioscler Thromb Vasc
Biol ,28:711-717